Research programme: anti-EpCAM CAR-T therapeutics - AffyImmune Therapeutics
Latest Information Update: 28 Aug 2024
At a glance
- Originator AffyImmune Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Jul 2020 Preclinical trials in Cancer in USA (Parenteral)
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in Cancer presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)